Cargando…
EQUITABLE ACCESS
The COVID-19 epidemic has once again highlighted the challenges to achieve equitable access to critical antimicrobials and vaccines. The problem is particularly acute for antimicrobials. Despite recent investments improving the pipeline for new treatments, most new treatments are not available to po...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186951/ http://dx.doi.org/10.1016/j.ijid.2023.04.112 |
_version_ | 1785042658022916096 |
---|---|
author | Balasegaram, Manica Cohn, Jennifer |
author_facet | Balasegaram, Manica Cohn, Jennifer |
author_sort | Balasegaram, Manica |
collection | PubMed |
description | The COVID-19 epidemic has once again highlighted the challenges to achieve equitable access to critical antimicrobials and vaccines. The problem is particularly acute for antimicrobials. Despite recent investments improving the pipeline for new treatments, most new treatments are not available to populations most in need, especially in low- and middle-income countries. Once a drug is approved a range of factors may hinder access, from lack incentives to register and commercialize products due to unattractive market potential to unfunded national action plans that can help improve the uptake and appropriate use of new tools to combat antibiotic resistance. Previous studies have shown that the majority of the 18 new antibacterials approved and launched between 2010-2020 were accessible in only 3 out of 14 high-income countries (Sweden, UK, and US). In low- and middle-income countries, the problem is even worse, with only 10 of the 25 new antibiotics that entered the market between 1999 and 2014 registered in more than ten countries. While lack of equitable access to life-saving medicines, diagnostics, and vaccines is not a new problem for infectious diseases, emerging opportunities and innovative approaches can help improve access globally. This talk will review promising recent developments in governance and collaborations, policies, economic models and initiatives that may help correct deadly inequities. For example, the objectives of the Access to COVID-19 Tools Accelerator may serve as model that convenes diverse actors to mount a coordinated access response which may be applied to access to other antimicrobials and vaccines. In addition, novel licensing agreements for access and stewardship to cefiderocol, an antimicrobial that is on the WHO Essential Medicines List can help serve as a pathfinder to accelerate equitable access to novel antimicrobials. The talk will also surface critiques of ongoing initiatives and raise questions for further study and discussion. |
format | Online Article Text |
id | pubmed-10186951 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101869512023-05-16 EQUITABLE ACCESS Balasegaram, Manica Cohn, Jennifer Int J Infect Dis S15: Antimicrobials and Vaccines–Equitable Global Access Date: Saturday, Nov 19, 2022 Time: 14:00-15:30 Venue: Conference Hall #3 (CH3) The COVID-19 epidemic has once again highlighted the challenges to achieve equitable access to critical antimicrobials and vaccines. The problem is particularly acute for antimicrobials. Despite recent investments improving the pipeline for new treatments, most new treatments are not available to populations most in need, especially in low- and middle-income countries. Once a drug is approved a range of factors may hinder access, from lack incentives to register and commercialize products due to unattractive market potential to unfunded national action plans that can help improve the uptake and appropriate use of new tools to combat antibiotic resistance. Previous studies have shown that the majority of the 18 new antibacterials approved and launched between 2010-2020 were accessible in only 3 out of 14 high-income countries (Sweden, UK, and US). In low- and middle-income countries, the problem is even worse, with only 10 of the 25 new antibiotics that entered the market between 1999 and 2014 registered in more than ten countries. While lack of equitable access to life-saving medicines, diagnostics, and vaccines is not a new problem for infectious diseases, emerging opportunities and innovative approaches can help improve access globally. This talk will review promising recent developments in governance and collaborations, policies, economic models and initiatives that may help correct deadly inequities. For example, the objectives of the Access to COVID-19 Tools Accelerator may serve as model that convenes diverse actors to mount a coordinated access response which may be applied to access to other antimicrobials and vaccines. In addition, novel licensing agreements for access and stewardship to cefiderocol, an antimicrobial that is on the WHO Essential Medicines List can help serve as a pathfinder to accelerate equitable access to novel antimicrobials. The talk will also surface critiques of ongoing initiatives and raise questions for further study and discussion. Published by Elsevier Ltd. 2023-05 2023-05-16 /pmc/articles/PMC10186951/ http://dx.doi.org/10.1016/j.ijid.2023.04.112 Text en Copyright © 2023 Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | S15: Antimicrobials and Vaccines–Equitable Global Access Date: Saturday, Nov 19, 2022 Time: 14:00-15:30 Venue: Conference Hall #3 (CH3) Balasegaram, Manica Cohn, Jennifer EQUITABLE ACCESS |
title | EQUITABLE ACCESS |
title_full | EQUITABLE ACCESS |
title_fullStr | EQUITABLE ACCESS |
title_full_unstemmed | EQUITABLE ACCESS |
title_short | EQUITABLE ACCESS |
title_sort | equitable access |
topic | S15: Antimicrobials and Vaccines–Equitable Global Access Date: Saturday, Nov 19, 2022 Time: 14:00-15:30 Venue: Conference Hall #3 (CH3) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186951/ http://dx.doi.org/10.1016/j.ijid.2023.04.112 |
work_keys_str_mv | AT balasegarammanica equitableaccess AT cohnjennifer equitableaccess |